Key Insights

Highlights

Treatment Research

6 treatments under study, led by Atsn101

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03920007Phase 1/2Active Not Recruiting

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Showing all 1 trials

Research Network

Common Treatments

  • Atsn1011
  • Trimethoprimpolymyxin B1
  • Triamcinalone Acetonide1
  • Atsn101 Diluent Solution1
  • Prednisone1

Active Sponsors

  • Atsena Therapeutics Inc.1

Related Conditions

  • Lca1
  • Leber Congenital Amaurosis1

Activity Timeline